Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Peritoneal dialysis solution with dextrose as osmotic agent; removes solutes and water across peritoneal membrane via diffusion and ultrafiltration.
Intraperitoneal administration of hypertonic dextrose solution creates an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and removal of uremic toxins through peritoneal dialysis.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)Acute kidney injury requiring peritoneal dialysis
Continuous ambulatory peritoneal dialysis (CAPD) for end-stage renal diseaseContinuous cyclic peritoneal dialysis (CCPD)Off-label: Acute kidney injury requiring peritoneal dialysisOff-label: Management of severe fluid overload unresponsive to diuretics
Intraperitoneal administration: 2 L per exchange, typically 4 exchanges daily (continuous ambulatory peritoneal dialysis). Dextrose 4.25% solution used for ultrafiltration. Dose adjusted based on body size and fluid status.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, or as prescribed for continuous ambulatory peritoneal dialysis (CAPD); may adjust volume and frequency based on patient's fluid and electrolyte status.
None Documented
None Documented
Not applicable as a drug; dextrose is rapidly metabolized; plasma half-life of glucose ~1.5-2 hours; continuous reabsorption in dialysis prevents accumulation.
Dextrose terminal half-life is approximately 1-2 hours in normal metabolism; in peritoneal dialysis, continuous removal leads to variable half-life depending on dwell time and ultrafiltration; clinical context: continuous exposure during dwell.
Dextrose absorbed systemically and metabolized via glycolysis; lactate buffer converted to bicarbonate in liver.
Dextrose undergoes rapid cellular uptake and metabolism via glycolysis and subsequent oxidative phosphorylation; minimal hepatic metabolism.
Peritoneal dialysis; effectively removed via peritoneal membrane during dialysis exchanges; systemic absorption of dextrose minimal; elimination primarily through dialysate outflow; renal excretion negligible in anuria.
Peritoneal dialysis solution; dextrose is metabolized and eliminated via peritoneal dialysis; approximately 70-80% of dextrose is absorbed systemically and metabolized; the non-absorbed fraction is removed with dialysate outflow; lactate (buffer) is converted to bicarbonate in the liver and eliminated via respiration and urine.
Not applicable; dextrose does not bind to plasma proteins.
Dextrose: negligible (<1%); not bound to proteins.
Not applicable; dextrose distributes throughout total body water (~0.55 L/kg); dialysate instilled volume is ~2 L per exchange.
Dextrose: Vd 0.2-0.4 L/kg (total body water); distributes throughout extracellular and intracellular fluid.
100% via intraperitoneal route as dialysate; dextrose absorbed systemically at ~10-20 g per exchange depending on dwell time and concentration.
Intraperitoneal: 100% (directly into peritoneal cavity); systemic absorption of dextrose occurs via peritoneal capillaries (70-80% absorbed over dwell).
No dose adjustment needed for impaired kidney function as drug is administered intraperitoneally for dialysis; however, monitor serum electrolytes and fluid balance.
No dose adjustment required for renal impairment; however, monitor serum electrolytes and fluid balance closely in patients with residual renal function.
No specific dose adjustment recommended. Caution in severe hepatic impairment due to potential lactic acidosis with dextrose-containing solutions.
No specific dose adjustment recommended; use with caution in severe hepatic impairment due to risk of electrolyte disturbances and fluid overload.
Intraperitoneal: 30-40 mL/kg per exchange, up to 1 L per exchange depending on body size; frequency as needed for dialysis. Dextrose concentration tailored to ultrafiltration needs.
Individualized based on weight, body surface area, and peritoneal dialysis prescription; typical exchange volume: 30-40 mL/kg per exchange, 4-5 exchanges per day for CAPD; adjust dextrose concentration based on ultrafiltration needs.
Start with lower volumes (e.g., 1.5-2 L per exchange) and monitor for fluid overload and glucose intolerance. Use lowest effective dextrose concentration to minimize hyperglycemia.
No specific dose adjustment; monitor for fluid overload and electrolyte imbalances, adjust dextrose concentration and exchange volume as needed, consider reduced volume and frequency in patients with compromised cardiac or renal function.
Not for intravenous use.
None.
["Monitor serum electrolytes, glucose, and fluid balance","Risk of peritonitis with catheter use","Hypokalemia or hyperglycemia possible","Not for IV administration"]
["Peritonitis: Use strict aseptic technique; monitor for signs of infection","Mechanical complications: Catheter malfunction, leakage, hernia","Metabolic disturbances: Hyperglycemia, hyperosmolarity, electrolyte imbalances","Hypersensitivity: Rare allergic reactions to components","Volume overload: Monitor ultrafiltration and body weight"]
["Pre-existing severe hyperglycemia","Hypersensitivity to any component","Documented loss of peritoneal function","Abdominal conditions compromising dialysis (e.g., recent surgery, adhesions)"]
["Pre-existing severe hyperglycemia","Hypersensitivity to dextrose or any component","Clinically significant peritoneal membrane abnormalities (e.g., extensive adhesions, recent surgery)","Severe respiratory acidosis (relative contraindication)"]
Data Pending Review
Data Pending Review
No specific food interactions. However, dietary restrictions typically include limiting sodium, potassium, phosphorus, and fluid intake as recommended by the nephrologist. Avoid high-potassium foods (e.g., bananas, oranges, tomatoes) and high-phosphorus foods (e.g., dairy, nuts, colas) to prevent electrolyte imbalances. Consult a renal dietitian for personalized meal planning.
No direct food interactions with Delflex-LM w/ Dextrose 4.25% as it is intraperitoneal. However, dietary restrictions for renal failure apply: limit sodium, potassium, phosphorus, and fluid intake. Dextrose absorption may affect blood glucose; diabetic patients should adjust diet and insulin accordingly.
Delflex w/ Dextrose 4.25% is a peritoneal dialysis solution. No direct fetal risks are expected from the solution itself; however, maternal metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) could affect the fetus. In the first trimester, uncontrolled diabetes may increase the risk of congenital anomalies. In the second and third trimesters, maternal hyperglycemia may lead to fetal macrosomia, neonatal hypoglycemia, and polyhydramnios.
Insufficient human data; animal studies not available. Icodextrin and dextrose are not known teratogens, but risks cannot be excluded. In first trimester, theoretical risk of metabolic disturbance; second and third trimesters, possible volume overload. Use only if clearly needed.
Dextrose and electrolytes from the solution may equilibrate with maternal plasma. Excretion into breast milk is likely minimal and not clinically significant. The M/P ratio is not established; however, the risk to the nursing infant is considered low. Monitoring infant for signs of electrolyte imbalance or hyperglycemia is prudent if maternal serum concentrations are elevated.
Unknown if icodextrin or dextrose metabolites excreted in human milk. M/P ratio not established. Caution in breastfeeding women; consider benefits vs risks.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics of components. No specific dose adjustments for Delflex w/ Dextrose 4.25% are established; however, frequent monitoring of maternal glucose and electrolytes is advised to adjust dialysis prescription as needed to maintain metabolic control.
No specific dose adjustments established; pharmacokinetic changes in pregnancy (increased plasma volume, renal function) may affect drug clearance. Monitor adequacy of dialysis and adjust exchange volume/frequency as needed to maintain target solute clearance and ultrafiltration.
Category C
Category C
DELFLEX W/ DEXTROSE 4.25% is a peritoneal dialysis solution used in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Monitor for signs of peritonitis, such as cloudy effluent, abdominal pain, and fever. Ensure strict aseptic technique during exchange to prevent infection. The 4.25% dextrose concentration is hypertonic and used for ultrafiltration in fluid overload. Check electrolyte levels regularly, especially potassium and magnesium, as dialysis can alter serum levels. Warm the solution to body temperature before use to improve comfort and dialysis efficiency.
Delflex-LM w/ Dextrose 4.25% is a peritoneal dialysis solution. Verify solution clarity and integrity before use. Warm solution to body temperature to minimize discomfort. Use aseptic technique for all connections to reduce peritonitis risk. Monitor effluent for clarity; cloudy effluent may indicate infection. Check blood glucose levels closely in diabetic patients due to dextrose absorption. Adequacy of dialysis should be assessed by Kt/V and creatinine clearance. Do not administer intravenously.
Wash hands thoroughly before handling the dialysis solution or performing exchanges.Use a clean, dry area for all exchanges and keep the catheter site clean and dry.Inspect the solution bag for cloudiness, leaks, or particulate matter before use; do not use if any are present.Do not reuse or refrigerate the solution; store at room temperature and protect from light.Report any signs of infection such as redness, swelling, or drainage at the catheter site, or cloudy effluent immediately.Follow your prescribed exchange schedule exactly to maintain proper fluid and waste removal.
Store solution at room temperature, avoid extreme heat or cold.Check solution bag for leaks, cloudiness, or discoloration before use; do not use if compromised.Warm the solution to body temperature (use dry heat, not microwave) before infusion.Perform exchange in a clean, well-lit area and wash hands thoroughly.Use sterile technique when connecting and disconnecting lines.Monitor your weight and blood pressure daily and report changes.Report any signs of peritonitis: cloudy effluent, abdominal pain, fever, nausea, or vomiting.Follow a renal diet as advised by your dietitian, including fluid, sodium, potassium, and phosphorus restrictions.Do not reuse solution or administration sets.Contact healthcare provider if you experience shortness of breath or swelling (signs of fluid overload).